2023 IMPACT REPORT
Philanthropic Leaders Catalyzing Innovation
Mission Hoag Innovators is a group of donors with a shared vision for advancing health care innovation at Hoag by leveraging the power of collective giving. The group is defined by its active engagement, discretionary review, and collaborative decision-making on which philanthropic investments will provide the greatest impact.
TABLE OF CONTENTS
Letter from the Founders
1
Impact
3
Financials
5
In Their Own Words
7
Project Investment Updates
13
Innovator of the Year
33
When we evaluated our philanthropic commitment to Hoag, we envisioned a platform for us and other like-minded donors to support multiple initiatives while learning and growing along the way. We are excited about how this dynamic group of donors is helping Hoag drive health care innovation here in our community and beyond. As we look to further our impact, we hope you will join us in inviting others to become Hoag Innovators." Robert and Kitty Brunswick Founding Hoag Innovators
Dear Hoag Innovators, What an amazing year it has been for Hoag Innovators! With 14 new member families joining over the past year, bringing our current total to 63 member families, our momentum and impact continue to build. When Hoag Innovators launched in 2017, we could not have imagined it would grow to what it is today. The media coverage Hoag Innovators has received over the past year is a humbling testament to our shared commitment to advancing health care innovation. Thank you for being an actively engaged Hoag Innovators member and for championing our mission among others in the community. Together, we have invested in a total of 16 projects that represent a wide range of disciplines at Hoag. Two of those projects are new to our investment portfolio this year, and they are detailed in the following pages along with updated results on all projects funded to date. As you will read throughout this report, the clinical leaders at Hoag are maximizing our investments to better serve patients in our community and contribute to the advancement of health care everywhere. Not only is this exciting to be part of, but it is also a compelling reason to further elevate Hoag
LETTER FROM THE FOUNDERS
Innovators and expand our impact. As we look to the future of Hoag Innovators, we are pleased to introduce additional recognition levels for potential and current members interested in increasing their impact on Hoag and involvement with the group. The long-term sustainability of Hoag Innovators is critical to ensure Hoag can continue leading the way in health care innovation and provide world-class care to our community. We look forward to sharing additional details. Thank you for your generosity and for being part of Hoag Innovators. It is an honor to invest, learn, and engage alongside you. Sincerely, Robert and Kitty Brunswick Founding Hoag Innovators
IMPACT Now in its fifth year of philanthropic investment, Hoag Innovators continues to empower Hoag to advance its innovation platform and push the limits of what is possible. Through support of groundbreaking projects across the organization, Hoag Innovators is strengthening Hoag’s position as a health care leader, building Hoag’s capacity to define the future of health care, and ensuring world-class care is available right here in our community.
HOAG INNOVATORS | IMPACT REPORT
IMPACT
Total Giving by Calendar Year
MILLION
7
$6,580,000*
6 $5,384,000
5
4
3
$2,465,000** $1,926,773
2
$1,771,982 $1,207,663
$1,150,000
2017
2018
1
0 2019
2020
2021
2022
2023
* Total includes funds provided by the Lori and Mike Gray matching gift challenge ** Donations as of September 28, 2023
4
Fund Allocation & Distribution Across Hoag
12%
Women’s Health Institute
52%
Hoag Family Cancer Institute
6%
Radiology & Imaging
6%
Jeffrey M. Carlton Heart & Vascular Institute
FINANCIALS
6%
Digestive Health Institute
HOAG INNOVATORS | IMPACT REPORT
8%
Pickup Family Neurosciences Institute
10%
Hoag-Wide Initiatives
FINANCIALS
NK Cell Therapy Program
Total Body Photography: VECTRA WB360 Whole-Body 3D Imaging
$500,000 Xenex® UV Germ-Zapping Robots Transitional Care Pilot
$180,000
$125k $125k $100k
Clinical Pilot of Cognivue
$400,000
Prostate Cancer Screening Clinic
$293,000
Mobile C-Arm Cios Spin Imaging Equipment
Cancer Early Detection Analysis Lab
$407,000
$350,000
Biocartis Idylla™ Technology
$150k
LEAF Device System Implementation in Critical Care Units
Invenio NIO Laser Imaging
$200,000
$125k
NIO Laser Imaging System
$250,000 Marfan Syndrome & Related Conditions Program
$250,000 Center for Artificial Intelligence and Advanced Imaging at Hoag = AI²
$250,000 Perinatal Nurse Navigator Program
$300,000
Hoag Pacify App
$175k
Giving by Fund (Total giving includes multi-year pledges and estate gifts)
Hoag Innovators Fund
$11,861,829
Hoag Innovators Endowment Fund
$10,639,534
Total funded projects (as of 5/31/23)
$4,055,000 6
HOAG INNOVATORS | IMPACT REPORT
IN THEIR OWN WORDS
The groundbreaking technology, pioneering programs, and innovative care practices funded by Hoag Innovators represent significant gains in health care, but the return on investment is perhaps best reflected in the lives impacted. On the following pages, grateful patients, family members, and Hoag staff share in their own words how advances made possible by Hoag Innovators have made a difference in their health and in their lives.
8
Patients, family members, and clinicians who have benefited from projects funded by Hoag Innovators share what it means to them. Jaimie, the nurse navigator, was monumental during my pregnancy, especially during the last months where I had a different doctor's appointment almost every other day. This was my first pregnancy, and I am over the age of 40. Our baby was diagnosed with Tetralogy of Fallot (TOF), so there was a lot that I was worried about. Jaimie was so professional, knowledgeable, kind, and the best advocate I could have asked for. She was on top of everything and really was the person between all of these different doctors to make sure important things were getting communicated to me. We couldn't have done this without her. I am eternally thankful for her knowledge and kindness.” Niyousha, Grateful Patient Perinatal Nurse Navigator Program
“The NIO Laser Imaging System has been a great learning tool to help in understanding the patient's diagnosis. It is also much more efficient than sending the specimens downstairs and waiting 20-30 minutes for a diagnosis.” Ciara, Clinical Resource Nurse for Neuro Spine Invenio NIO Laser Imaging System
HOAG INNOVATORS | IMPACT REPORT
IN THEIR OWN WORDS
“I left my skin cancer screening appointment with Dr. Wang with full confidence that nothing was missed. The handheld digital dermatoscope funded by Hoag Innovators that he used as part of the screening magnified areas of concern, including very small moles that were barely visible, to ensure precision and accuracy." Kyle, Grateful Patient VECTRA WB360 Whole-Body 3D Imaging
“Let me say how amazing Jaimie Shane is! For my birthing process, she is the reason I was assisted with so many things. When Jaimie saw me struggling to set up my cardiologist appointment just days before my cesarean, she jumped right in, made the necessary phone calls, and accomplished what I couldn’t. The tour she gave me of the birthing suite and showing me what to expect was needed and necessary. It’s because of Jaimie that my questions were answered and I was able to take a breath and know my husband and I were not alone in this process!” Lauren, Grateful Patient Perinatal Nurse Navigator Program
“Having the Xenex robot gives me additional peace of mind in knowing that we have an additional layer of antimicrobial protection for our patients.” Todd, Charge Nurse Xenex® UV Germ-Zapping Robots
10
The Gift of New Hope The NK cell therapy pancreatic cancer clinical trial at Hoag, headed by Dr. Seery and her dedicated team, has truly been a lifeline for our family." "My wife and I were battling our way back from a serious bout of COVID-19 hospitalization. Amidst our own recovery, we received the shattering news of my mom's pancreatic cancer diagnosis. We were devastated. As Sun’s primary caretakers, we extensively searched for viable treatments within the San Diego area (where we live). At the time, about three years ago, options for pancreatic cancer treatment were scarce, and we reluctantly began the arduous path of traditional chemotherapy and pain management. But as the months rolled on, mom’s condition only worsened. The tumors grew larger, and we found ourselves transitioning to the next phase of traditional treatments. Sun always has been an active person who relished cooking, gardening, and occasional getaways with friends. None of that was possible now. She was confined to bed, enduring unbearable pain throughout her treatment. It was a heart-wrenching time for our family, feeling helplessness and grief. During this struggle, we relentlessly scoured for alternatives. We wanted to exhaust every possible option, so we had no regrets looking back. It was during this turbulent period that we crossed paths with a surgeon at Hoag, who introduced us to Dr. Seery, who heads the clinical trial.
HOAG INNOVATORS | IMPACT REPORT
IN THEIR OWN WORDS
Living with a pancreatic cancer patient is challenging. Countless hours were spent in hospitals, grappling with emergencies and procedures. Each day was marked by an undercurrent of apprehension. However, the clinical treatment offered at Hoag was a lifesaver for our family. The cancer's relentless progression was stalled. Nearly three years have passed since that initial diagnosis, and the tumor's grip has been held at bay. Dr. Seery and her team have been nothing short of exceptional, addressing our every concern with compassion and expertise. This treatment has not only brought stability to Sun's life, but it has also significantly enhanced the quality of life for our entire family. The stress has diminished, the situation is more manageable, and moments of joy have once again found their place in our lives. Though Sun may still spend considerable time in bed, she is no longer imprisoned by pain. With the aid of the treatment, she enjoys nurturing her garden, despite the occasional battle against mischievous squirrels. She also enjoys spending time with us helping prepare meals whenever she can. The circumstances we find ourselves in are far from ideal, yet I am unable to ask for more. The clinical trial has not just extended mom’s life, but it has also rekindled hope, strength, and a renewed appreciation for the moments we share.” KC, Grateful Family Member NK Cell Therapy Program
12
PROJECT INVESTMENT UPDATES HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Innovative Care Practice Prostate Cancer Screening Clinic
INVESTMENT DATE
Spring 2023 INVESTMENT AMOUNT
The Right Screening for the Right Person at the Right Time
$293,000 THE CHALLENGE According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer. One man in eight will be diagnosed with prostate cancer during their lifetime, and one man in 41 will die from prostate cancer. Historically, prostate cancer screening tools and practices have been limited, but with recent innovations in tests and detection technologies, there is an opportunity to significantly improve the prostate cancer screening process. THE INNOVATION The Prostate Cancer Screening Clinic will bridge the gap between basic screening in a primary care office and advanced screening in a urologic oncology office. A dedicated nurse practitioner will see patients and provide screenings at the clinic using different advanced tools, allowing Hoag’s urologic oncologists to focus on treatment. Working collaboratively with Hoag Medical Group, the Prostate Cancer Screening Clinic will help ensure the right screenings are consistently offered to the right patients. THE RESULTS Hoag’s urologic oncology team is currently developing plans for the clinic. Support from Hoag Innovators has been leveraged to secure additional philanthropic gifts from grateful patients of Drs. Bassett and Torrey, funding the first three years of clinic operations.
14
Perinatal Nurse Navigator Program
INVESTMENT DATE
Fall 2022 INVESTMENT AMOUNT
$300,000
Alleviating Stress and Optimizing Outcomes for Patients with High-Risk Pregnancies
THE CHALLENGE Hoag is the second-busiest maternity center in California, with approximately 8,000 deliveries each year. A number of these pregnancies are considered high risk, and about 10% of babies born at Hoag are admitted to the neonatal intensive care unit (NICU). Being diagnosed with a high-risk pregnancy can be overwhelming and difficult to navigate. It often requires care from multiple specialists and a coordinated, comprehensive plan to ensure a healthy pregnancy, delivery, and beyond. THE INNOVATION The perinatal nurse navigator provides personalized support, resources, education, and guidance to patients at Hoag with high-risk pregnancies. Through coordinating consults and multidisciplinary conferences with specialists and communicating vital information between providers, the perinatal nurse navigator helps ensure optimal conditions for birth and a comprehensive postnatal care plan for the baby. Thanks to the perinatal nurse navigator, patients faced with the stress and challenges of a highrisk pregnancy can rest assured knowing they will have a personal guide throughout their experience, and both mother and baby will receive the most comprehensive care Hoag can provide. THE RESULTS
HOAG INNOVATORS | IMPACT REPORT
•
Enrollment in the Perinatal Nurse Navigator Program increased by 456.7% from the previous year.
•
Rates of ICU admission for placenta previa decreased by 44.4%.
•
From January–July 2023, there were 148 preadmission anesthesiology and neonatology consults, a 26.5% increase compared to the same period in 2022.
•
14 multidisciplinary conferences.
•
Hoag is elevated in its provision of service-oriented and patientcentered care on par with larger institutions with this capability.
PROJECT INVESTMENT UPDATES
NK Cell Therapy Program
INVESTMENT DATE
Fall 2020 INVESTMENT AMOUNT
Revolutionizing Pancreatic Cancer Treatment
$500,000 THE CHALLENGE Considered one of the deadliest cancers, pancreatic cancer is one of the few cancers for which there has not been substantial treatment advancements. Currently, only 9% of individuals diagnosed survive for five years or longer. The median survival prognosis is five to eight months. Pancreatic cancer is estimated to become the second-leading cause of cancer death by 2030. Effective therapy for pancreatic cancer is needed. THE INNOVATION The Hoag Family Cancer Institute is one of only two sites in the country to offer the most advanced immunotherapy clinical trial currently available for the treatment of locally advanced and metastatic pancreatic cancer. In partnership with leading immunotherapy company ImmunityBio, the phase II trial uses innovative NK (natural killer) cells, which are manipulated to recognize and target cancer cells. When injected into the patient, the NK cells activate the patient’s immune system to create antibodies that fight cancer in combination with chemotherapy. THE RESULTS •
A total of 109 patients were enrolled in the NK cell therapy pancreatic cancer clinical trial, with 54 patients receiving treatment at Hoag.
•
The trial is now closed to new enrollment. Two patients remain in active treatment with one patient in their 31st month on the trial.
•
Though results are not yet finalized, results of the NK cell therapy pancreatic cancer clinical trial to date show the median overall survival for those in the trial is more than double the typical survival for these advanced cases of pancreatic cancer.
16
Marfan Syndrome & Related Conditions Program Expert Care Locally for Patients with Rare Disease
INVESTMENT DATE
Spring 2019 INVESTMENT AMOUNT
$250,000 THE CHALLENGE Marfan syndrome and related conditions are rare and life-threatening genetic disorders that put patients at risk for aortic disease and dissection. Few programs exist in the U.S., so many patients must travel for expert care. THE INNOVATION World-renowned cardiologist Dr. David Liang, who was recruited from Stanford thanks in part to the investment provided by Hoag Innovators, leads Hoag’s multidisciplinary team of experts at Hoag’s comprehensive Marfan Syndrome & Related Conditions Program. The only comprehensive Marfan syndrome program in Southern California, it’s also the only one at a community hospital in the United States. THE RESULTS
HOAG INNOVATORS | IMPACT REPORT
•
82 families cared for with connective tissue disorders.
•
48% increase in patient volume from 2022 to 2023.
•
Hoag’s program has diagnosed pathogenic mutations (connective tissue disorders) in 60 new patients.
•
The program is projected to complete over 250 genetic tests this year, a 25% increase from 2022.
PROJECT INVESTMENT UPDATES
Hoag Innovators’ impact on the organization is exponential. Their support helps power Hoag’s commitment to continuous innovation, which is a direct benefit to our patients. The Hoag Innovators model inspires and motivates Hoag’s talented clinicians to dream big and consider what else can be done to provide better care, improving the health and well-being of our community at large. It has also become a powerful recruitment tool, positioning Hoag to attract talented physicians at the top of their fields from across the country who are as committed to innovation as Hoag is.” Robert T. Braithwaite President and Chief Executive Officer, Hoag
18
Technology and Equipment Mobile C-Arm Cios Spin Imaging Equipment Improving Outcomes and Comfort for Patients with Pulmonary Disorders
INVESTMENT DATE
Spring 2023 INVESTMENT AMOUNT
$407,000 THE CHALLENGE Traditional diagnostic and therapeutic options for patients with pulmonary disorders, including lung cancer, are invasive and uncomfortable with a 25% rate of medical complications. THE INNOVATION This real-time 3D imaging technology will be utilized during roboticassisted bronchoscopies for patients with lung cancer and other pulmonary disorders. With the mobile C-arm Cios Spin system, surgeons receive 3D confirmation of positioning while a robotic bronchoscope is advanced through the airway, which eliminates the need for incision and provides a 90% or higher accuracy rate with complication rates below 2%. It is also significantly more comfortable for the patient, leads to fewer follow-up procedures, and allows for diagnosis and treatment of a lesion in the same procedure. THE RESULTS The equipment has been installed in Hoag’s Newport Beach Advanced Endoscopy Center and started being used on patients in September 2023. The equipment will further elevate Hoag’s position as the preeminent leader in minimally invasive, robotic-assisted surgeries in Orange County. It also provides Hoag the opportunity to lead innovation in clinical trials using ablation techniques for intrathoracic malignancies. Hoag has launched an extensive media campaign to announce the equipment, including information about the funding from Hoag Innovators.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Invenio NIO Laser Imaging System
INVESTMENT DATE
Fall 2022 INVESTMENT AMOUNT
$250,000
Increasing Efficiency and Accuracy of GI Biopsy Procedures
THE CHALLENGE Hoag performs over 4,000 tissue biopsies per year for diagnostic and treatment planning. With the traditional method, frozen tissue samples take 30-45 minutes to transport to the lab and process, and this procedure may need to be repeated multiple times before the sample contains diagnostic cells. Further, the frozen tissue samples can contain artifacts, which decreases the accuracy of the sample. An improved tissue sampling method allows physicians to spare as much healthy tissue as possible while saving time and increasing accuracy. THE INNOVATION The NIO Laser Imaging System creates high-digital microscopic images of unprocessed tissue in under three minutes with a considerable degree of accuracy. Support from Hoag Innovators in 2019 enabled Hoag to be an early adopter of the NIO Laser Imaging System for neurosurgery. Use of the NIO Laser Imaging System is a novel approach for GI biopsies that leads to overall faster GI procedures by expediting diagnosis and decreasing anesthesia time for the patient. The laser increases accuracy, which saves healthy tissue from being removed, improves efficiency, and decreases procedure costs. The sample can be analyzed in Hoag’s GI Lab in less than three minutes. For a procedure that would take 160 minutes through surgery, NIO can be completed in eight minutes. THE RESULTS Since installation of the NIO Laser Imaging System at Hoag’s GI Lab in March of 2023, over 75 cases have been completed. The system has revolutionized intraoperative diagnosis of pancreatic cancer at Hoag using laser imaging and AI. Hoag was the first in the world to present the use of NIO for endoscopic ultrasound (EUS)-guided biopsy of pancreatic masses at the Digestive Disease Week exhibit in Chicago, IL. Additionally, Dr. Phuong Nguyen, medical director of the Hoag Advanced Endoscopy Center, co-presented a live demo during the Association of Women Endoscopists week in San Diego, CA. Planning for a multi-center study with Harbor-UCLA Medical Center and UCSD is underway to develop an AI algorithm to be used with NIO for pancreatic biopsies, and Hoag will be the first in the U.S. to conduct a study for FDA clearance of an AI algorithm for lung biopsies. NIO has also expanded into interventional pulmonology at Hoag with more than 50 cases completed to date. 20
Total Body Photography: VECTRA WB360 Whole-Body 3D Imaging Improving Skin Cancer Early Detection
INVESTMENT DATE
Spring 2022 INVESTMENT AMOUNT
$400,000 THE CHALLENGE Melanoma is the deadliest form of skin cancer, and Southern California has one of the highest incidences of the disease in the world. Implementing better methods of early detection, especially for those at increased risk of developing melanoma and other skin cancers, can save lives. THE INNOVATION The VECTRA WB360 whole-body 3D imaging system uses 92 cameras that spontaneously fire to capture 3D total body images, allowing patients to have all their moles and lesions mapped out in less than two seconds. The technology allows clinicians to track changing lesions, identify those of concern, and detect melanoma and other skin cancers sooner than with traditional detection methods. The technology not only reduces the number of unnecessary biopsies, it also fundamentally changes the way dermatologists deliver care to high-risk patients with a history of skin cancer. Thanks to the support of Hoag Innovators, Hoag was the first institution in California to adopt VECTRA WB360 whole-body 3D imaging, joining the ranks of Memorial Sloan Kettering Cancer Center and Johns Hopkins Medicine. THE RESULTS The VECTRA WB360 whole-body 3D imaging system was installed and has been operational since May 2023. As of September 2023, 74 patients have been scanned. Hoag’s use of the VECTRA system received media coverage from multiple outlets, including ABC, CBS, and the OCBJ, which included promotion of Hoag Innovators’ role in providing funding. Funds from Hoag Innovators’ investment also supported the acquisition of five D200 handheld digital dermatoscopes, which are smaller scanning devices used daily in Hoag’s Melanoma & Skin Cancer Program to detect lesions. With the new technology, the Hoag team has detected 30 melanomas, 86 basal cell carcinomas, and 72 squamous cell carcinomas.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Clinical Pilot of Cognitive Screening in Acute Care Settings: Cognivue Setting the Standard for Cognitive Health Assessments
INVESTMENT DATE
Spring 2022 INVESTMENT AMOUNT
$200,000 THE CHALLENGE There is no current standard of care for assessing cognitive health within the U.S. In addition to increased age, a number of medical conditions, diseases, and health episodes can cause cognitive decline. Identifying changes in cognitive function at the earliest possible time will help ensure appropriate triage and diagnosis, ultimately leading the patient to the right treatment plan sooner. THE INNOVATION Cognivue is the first FDA-cleared technology for self-administered computerized cognitive assessment. Test results are provided for six cognitive domains, including visual perception, attention, language, memory, delayed recall, and abstraction. With Hoag Innovators’ funding, Hoag was the first in Southern California to implement Cognivue to conduct routine cognitive function screenings across a broad range of neurological disorders. THE RESULTS •
Cognivue devices have been deployed in Hoag’s Epilepsy Monitoring Unit and Outpatient Neuropsychological Assessment Clinic.
•
600 patients have received neurological assessments with Cognivue through the clinical pilot to date.
•
Because diabetes is a significant risk factor for cognitive decline, Hoag’s Memory & Cognitive Disorders Program is partnering with the Mary & Dick Allen Diabetes Center to implement Cognivue screenings for diabetes patients at the center.
22
Biocartis Idylla™ Technology Platform for Molecular Diagnostics Testing and Translational Pathology Increasing the Speed of Cancer Diagnosis
INVESTMENT DATE
Spring 2021 INVESTMENT AMOUNT
$150,000 THE CHALLENGE Every patient’s cancer is unique. Through the molecular testing of tumors, gene abnormalities or mutations causing a patient’s cancer can be identified, which is the key to unlocking the treatment that will be most effective. Performing molecular testing in-house instead of using an outside laboratory can save precious time when it comes to diagnosis and initiation of a targeted treatment plan while decreasing cost. THE INNOVATION The Biocartis Idylla™ Technology Platform is a fully automated, real-time molecular testing system for in-house molecular testing for cancer patients to guide targeted, personalized treatment decisions. THE RESULTS The Idylla™ has been validated for the BRAF gene mutation for several cancers, including melanoma, thyroid cancer, and colon cancer, and patient testing began in August 2023. The Precision Medicine Program is monitoring the test ordering process, platform stability, and results before expanding into lung and other cancer types. Use of the Idylla™ along with Hoag’s digital pathology capabilities are attracting interest from potential research partners, including pharmaceutical companies and AI and technology startups.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Center for Artificial Intelligence and Advanced Imaging - AI 2 Harnessing the Power of AI to Improve Imaging
INVESTMENT DATE
Spring 2021 INVESTMENT AMOUNT
$250,000 THE CHALLENGE With advances in CT technology, the amount of data and information presented to the radiologist is immense. Imaging studies that once consisted of 50-60 slices through a region of the body now comprise hundreds or even thousands of images. These data-rich exams must be carefully but expeditiously evaluated to diagnose subtle abnormalities that may be life threatening. THE INNOVATION Artificial intelligence is at the forefront of the national conscience with a range of applications from mundane to labor-intensive tasks. In the past few years, medical imaging companies have concentrated on developing algorithms to assist in the detection and timely reporting of critical abnormalities on CT scans. The Hoag Innovators’ investment will help bring artificial intelligence to the Radiology Department at Hoag. THE RESULTS Hoag Radiology partnered with Aidoc, an industry-leading AI company specializing in lesion detection and care team coordination. Hoag’s radiology team implemented five algorithms to detect pathology on CT scans: intracranial hemorrhage, pulmonary embolism, incidental pulmonary embolism, aortic dissection, and rib fracture. The team also worked with Aidoc to develop care team notification tools that allow the radiologist to immediately convey important imaging findings to the appropriate care team through an encrypted smartphone app. The combination of rapid diagnosis along with expedited care team notification has resulted in further improvements in the ability of Hoag physicians to deliver life-saving treatments when minutes matter. Since July of 2022: •
105,000 imaging studies at Hoag have been analyzed with Aidoc.
•
4,400 studies were flagged with positive findings.
•
80 workstations at Hoag are running Aidoc.
24
Cancer Early Detection Analysis Lab
INVESTMENT DATE
Spring 2021 INVESTMENT AMOUNT
$350,000
Identifying Cancer Recurrence Sooner
THE CHALLENGE Using innovative applied genomics technology, physicians can develop a personalized, non-invasive approach to each cancer survivor’s post-treatment surveillance. Cancer recurrence is a significant risk for many cancer survivors, and this new technology can help physicians detect cancer recurrence at the earliest possible stage, offering the best chance at successful treatment. Providing physicians with timely data can also indicate when conventional treatments are not working, allowing for immediate treatment revisions and alterations. THE INNOVATION Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) provides analysis of the protein content of exosomes, small vesicles produced by cancer cells that contain DNA, RNA, microRNA, lipids, and proteins. Hoag’s precision medicine team will use this new technology in a clinical research study to develop personalized protein signatures to create biomarkers by analyzing patient blood and/or urine samples. Samples will be obtained prior to, during, and after cancer surgery and treatment, providing a longitudinal set over the course of their disease. These real-time samples will identify protein increases or spikes in patients, indicating cancer recurrence or growth sooner than traditional methods. THE RESULTS The Hoag Translational Lab at University Lab Partners has been established, and initial experiments have been conducted at a proteomics facility shared with UCI. The Bruker microflex® MALDI-TOF machine has been ordered, which will allow Hoag’s team to scale and conduct experiments in the Hoag Translational Lab. The precision medicine team has undergone training from Biological Dynamics, Inc. and Bruker, the vendors for the exosome isolation instrument and laser, respectively. To date, 43 patients have been enrolled in the Individual Biomarker Development in Patients Treated for Cancer Study, and preoperative levels have been obtained. Hoag’s team is tracking initial results from before and after cancer surgery and is continuing to optimize experimental protocols before scaling up.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Invenio NIO Laser Imaging
INVESTMENT DATE
Fall 2019 INVESTMENT AMOUNT
Reducing Length of Surgery for Patients
$125,000 THE CHALLENGE Pathology examination of specimens removed during surgery can take up to 30 minutes before surgery can continue. Adopting novel pathology and imaging technology can decrease time spent in surgery by minimizing the wait for pathology analysis of the patient’s specimens. THE INNOVATION The NIO pathology and slide imaging system allows examination of specimens from multiple sites in the patient in real time, rather than waiting 30 minutes or more for each sample to be analyzed in the pathology lab. The high quality of the Invenio images allows neurosurgeons to make a more accurate diagnosis in some cases. To maximize the technology even further, Hoag’s team established connectivity to Ambra, a cloud-based image management system, to web stream images directly from the OR to the lab, enabling further streamlining and more rapid diagnosis. The Hoag team also recently activated the system’s artificial intelligence feature, which sends an AI diagnosis via text message to the surgeon within five minutes. THE RESULTS •
As of August 2023, a total of 494 neuro cases have been completed with the Invenio NIO Laser Imaging System.
•
Average time savings compared with conventional frozen section is 25 minutes.
•
Thanks to Hoag Innovators’ investment, Hoag was one of the first in the country to use Invenio. Since then, it has been implemented at many top-tier medical institutions, including academic medical centers which are now publishing results demonstrating its effectiveness.
26
LEAF Device System Implementation in Critical Care Units Preventing Pressure Injuries to Critical Care Patients
INVESTMENT DATE
Spring 2019 INVESTMENT AMOUNT
$125,000 THE CHALLENGE Patients endure painful hospital-acquired pressure injuries (HAPIs)— injuries to the skin or underlying tissue from prolonged pressure—when their mobility is limited or when they are unable to change positions in bed. HAPIs can complicate a patient’s recovery, but they can be prevented through timely patient repositioning. THE INNOVATION The LEAF System is an innovative monitoring system that uses a sensor adhered to the patient’s chest to detect their position and movement. The care provider can remotely monitor and reposition the patient at exactly the right time to prevent injuries from prolonged pressure. The LEAF System is currently being used in Hoag’s Critical Care Units (CCUs). THE RESULTS
HOAG INNOVATORS | IMPACT REPORT
•
93% turn protocol adherence (turn protocol adherence > 85% has been shown to significantly reduce hospital-acquired pressure injuries. Literature shows hospitals without LEAF monitoring have a baseline turn protocol adherence between 38% to 52%).
•
88% overall reduction in total hospital-acquired pressure injuries in CCUs.
•
With the success of the LEAF System on high-risk patients in Hoag’s CCUs, the Hoag patient safety team is making plans to expand the use of LEAF in other inpatient units.
PROJECT INVESTMENT UPDATES
Completed Projects Xenex® UV Germ-Zapping Robots Exceeding Infection Prevention Standards
INVESTMENT DATE
Spring 2020 (Reallocation from Bioquell ProteQ Bio-Decontamination System) INVESTMENT AMOUNT
$180,000 FINAL REPORT PRESENTED
Spring 2022 THE CHALLENGE Hoag’s commitment to infection prevention and patient safety drives the organization’s continuous search for innovative ways to enhance the hospital’s cleaning and disinfecting processes, which became more important than ever with the onset of the COVID-19 pandemic. THE INNOVATION Xenex® UV Germ-Zapping Robots provide an additional layer of protection against the bacteria and germs that can lead to health careassociated infections and surgical site infections. The robots use UV technology to disinfect the area without causing damage to hospital surfaces and are used following Hoag’s rigorous manual cleaning process by our environmental services (EVS) team. THE END RESULT The Xenex® UV Germ-Zapping Robots are deployed in operating rooms and other inpatient areas at Hoag Hospital Newport Beach and Hoag Irvine, providing additional cleaning and disinfection protection and ensuring the highest levels of patient and staff safety.
28
Hoag Pacify App Supporting Healthy Moms and Babies
INVESTMENT DATE
Fall 2019 INVESTMENT AMOUNT
$175,000 FINAL REPORT PRESENTED
Fall 2022 THE CHALLENGE During the early days of a newborn baby’s life, parents need fast answers and resources they can trust. Providing virtual and convenient support to mothers and their babies can help make the transition from the delivery room to the home environment smoother. THE INNOVATION The Hoag Pacify app allows for virtual, 24/7, on-demand access to helpful postpartum resources, including lactation consultants, nutritionists, midwives, and social workers. Available in both English and Spanish, the app serves as critical support at the stage moms need it most. With the onset of the COVID-19 pandemic in early 2020, the ability to access this type of help remotely became even more essential. The Hoag Pacify app is a component of the Women’s Health Institute’s 4th Trimester Program, which was designed to provide comprehensive, personalized support to parents from immediate postpartum through the first year of their baby’s life. THE END RESULT Approximately 3,500 new moms placed more than 6,000 calls with the Hoag Pacify app. Hoag Innovators’ support for Pacify enabled Hoag to demonstrate proof of concept, functionality, and market interest for development of a Hoag-built app—Nona—that is now available to patients and offers expanded support for both pregnant women and new moms.
HOAG INNOVATORS | IMPACT REPORT
PROJECT INVESTMENT UPDATES
Transitional Care Pilot Program
INVESTMENT DATE
Fall 2019 INVESTMENT AMOUNT
$100,000
Preventing Hospital Readmissions
FINAL REPORT PRESENTED
Spring 2023 THE CHALLENGE Patients with multiple, complex medical conditions face obstacles in their recovery upon discharge from the inpatient setting. From an inability to follow up with their physician or obtain prescribed medications to difficulty reconciling those new medications with the previous ones to simply not having access to groceries for healthy meals, difficulties can lead to emergency department visits and hospital readmissions. THE INNOVATION Hoag launched the one-year Transitional Care Pilot Program, funded by the Hoag Innovators, to develop a better way to support these patients. Those enrolled in the pilot received post-discharge home health care and resource coordination designed to help them navigate their complex medical journey, reduce length of stay, and prevent unnecessary hospital readmissions and ER visits. THE END RESULT The pilot provided a deeper understanding of what is required to provide effective post-discharge care coordination for medically complex patients. It demonstrated a 50% reduction in the rate of hospital readmission following intervention and served as a proof of concept for successful delivery of acute services in the home setting. This knowledge is being scaled to serve additional patients.
30
HOAG INNOVATORS | IMPACT REPORT
In today’s environment of increasingly tight hospital margins, philanthropy is the difference maker in a health system’s ability to invest in innovation. We are incredibly grateful to Hoag Innovators whose support has allowed Hoag to not only pursue but prioritize a robust innovation platform.” Andrew Guarni Executive Vice President and Chief Financial Officer, Hoag
32
Hoag Innovators Co-Founder Robert Brunswick Receives Orange County Business Journal ’s 2023 Innovator of the Year Award As Hoag Innovators continues to attract recognition in the community and in the media, one honor stands out as especially meaningful. The Orange County Business Journal ’s (OCBJ ) Innovator of the Year Awards honor, recognize, and celebrate individuals and their organizations who are creating game-changing products and services and demonstrate brilliance and leadership in innovation. More than 60 business and community leaders were nominated for the 2023 awards, including Hoag physician Dr. Steven Wang and Hoag Innovators Co-Founder Robert Brunswick. Robert was selected as one of five recipients of the Innovator of the Year Award and recognized for his visionary work in establishing Hoag Innovators. A dedicated supporter and ambassador of Hoag for many years, Robert, along with his wife Kitty, had a vision in 2017 for a novel approach to philanthropy to drive innovation at Hoag and make a significant impact on patients and the community. In co-founding Hoag Innovators, Robert has
HOAG INNOVATORS | IMPACT REPORT
established one of the fastest growing and most engaged philanthropic groups at Hoag that has accelerated innovation across the organization and in the health care space at large. OCBJ ’s Innovator of the Year Award is a reflection of Robert’s pioneering spirit and determined pursuit of innovation to elevate the lives of others. It is also recognition of the rapidly growing impact of Hoag Innovators. “I learned as an entrepreneur that to innovate you need to be willing to break the status quo and embrace change. I’m confident that Hoag Innovators is being recognized for doing just that in the world of philanthropy,” Robert shared upon accepting the 2023 Innovator of the Year Award. “I thank the 63 families who have invested with us through Hoag Innovators so we can do more good work. Stay tuned, we’re just getting started.” Congratulations, Robert, on this well-deserved honor, and thank you for your vision and bold leadership. The Hoag Hospital Foundation also proudly congratulates Dr. Steven Wang, director of dermatologic oncology at the Hoag Family Cancer Institute, for being nominated for the OCBJ 2023 Innovator of the Year Awards. With funding from Hoag Innovators, Dr. Wang led the charge to make Hoag the first hospital on the West Coast to offer high-risk skin cancer patients access to the VECTRA WB360, the world’s first whole-body 3D imaging system, which is now serving patients at Hoag.
Robert Brunswick with fellow winners of the Orange County Business Journal Innovator of the Year Award at the awards luncheon on September 7, 2023.
34
For more information about Hoag Innovators, please contact Gwen Ritter, vice president of development, principal gifts, at (949) 764-7209 or Gwen.Ritter@hoag.org.